• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.44% Nasdaq Down0.37%

    iBio, Inc. (IBIO)

    0.69 Up 0.01(1.50%) Nov 30, 4:03PM EST
    ProfileGet Profile for:
    iBio, Inc.
    600 Madison Avenue
    Suite 1601
    New York, NY 10022
    United States - Map
    Phone: 302-355-0650
    Website: http://www.ibioinc.com

    Index Membership:N/A
    Full Time Employees:9

    Business Summary 

    iBio, Inc., a biotechnology company, focuses on commercializing its proprietary plant-based protein expression technologies in the United States and internationally. The company’s proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that is designed to improve the potency and duration of effect of prophylactic and therapeutic vaccines. Its therapeutic protein product candidates comprise IBIO-CFB03, a product for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis, and other fibrotic diseases; C1 esterase inhibitor, a plasma-derived protein; Alpha-Galactosidase, an enzyme replacement product; and Palivizumab, a monoclonal antibody. The company’s vaccine candidates include H1N1 Influenza and H5N1 Influenza vaccines, which have completed Phase I human clinical trial; Yellow Fever vaccine and Papillomavirus therapeutic vaccine that are in preclinical stage; and malaria and hookworm parasitic pathogen vaccines, which are in Phase I clinical trial. Its biodefense product candidates include Anthrax/Plague bacterial disease vaccine; and Anthrax, a monoclonal antibody. The company has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor. It also has a collaboration and license agreement with FioCruz for the use of its proprietary technology in connection with the development, manufacture, and commercialization of vaccines; and a license and collaboration agreement with Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. iBio, Inc. is based in New York, New York.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on iBio, Inc.

    Key Executives 
    Mr. Robert B. Kay , 75
    Exec. Chairman and Chief Exec. Officer
    Mr. Robert L. Erwin , 62
    Mr. Mark Giannone , 58
    Chief Financial Officer
    Mr. Terence E. Ryan Ph.D., 60
    Chief Scientific Officer
    Mr. Douglas Hicks ,
    Sr. VP of Bus. Devel. & Strategy
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders